Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $1.36 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.